Piper Sandler initiated coverage of Labcorp with a Neutral rating and $235 price target The firm sees LabCorp as leading the industry in diagnostics services for decades. The analyst anticipates mid single digit revenue growth and close to 10% earnings growth. However, with the stock’s run over the last six months, Piper thinks the risk/reward is balanced at these levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Q3 2024 Earnings Release and Conference Call
- Labcorp price target lowered to $240 from $250 at Evercore ISI
- Labcorp price target raised to $265 from $245 at Jefferies
- Labcorp price target raised to $282 from $278 at Baird
- Labcorp Executives to Present at Global Healthcare Conference